ArticleJournal of separation science2026
Exploring the Active Components of Buqi-Zhitong-Decoction and Its Therapeutic Potential for Chronic Fatigue Syndrome Based on LC-MS/MS and Network Pharmacology.
Article in Journal of separation science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic fatigue syndrome (CFS) is a complex condition that requires effective intervention and treatment. Buqi-Zhitong-Decoction (BQZTD), an empirical formula, has been used clinically to treat CFS and has shown good clinical results. However, the underlying bioactive components and mechanism of action for its treatment of CFS remain unclear. This study is based on the serum pharmacochemistry method, utilizing LC-MS/MS technology for detection and analysis of BQZTD water extracts and their components entering the bloodstream. A total of 98 compounds were preliminarily identified from the BQZTD. Furthermore, 44 ingredients were detected in rat serum, including 19 prototype components and 25 metabolite components. The results of network pharmacology analysis indicated that the BQZTD might improve CFS by regulating immune, inflammatory, neuroendocrine system, and energy metabolism-related pathways. In addition, Prostaglandin-Endoperoxide Synthase 2 (PTGS2) plays a central role in the regulatory network. Molecular docking simulations with six potential active components in serum revealed that all of them exhibit high affinity for PTGS2, with compound Isoformononetin showing the strongest binding affinity. This study represents the first comprehensive identification of the chemical components, targets, and signaling pathways of BQZTD, clarifying its potential mechanism of action in treating CFS. The research findings provide a reference basis for pharmacodynamic studies and quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.